|Year : 2021 | Volume
| Issue : 6 | Page : 665-669
Levels of salivary immunoglobulin a and immunoglobulin G in type 2 diabetic patients
Olatunde A Olayanju1, Olabisi Bamidele2, Bola J Eseile3, Chioma Udeh3, Gabriel N Odok3, Nnaemeka E Awah3, Izuchukwu N Mba4, Fayeofori M Abbiyesuku2
1 Department of Chemical Pathology, University College Hospital, Ibadan; Department of Chemical Pathology, Babcock University Teaching Hospital, Ilisan, Nigeria
2 Department of Chemical Pathology, Babcock University Teaching Hospital, Ilisan, Nigeria
3 Department of Chemical Pathology, University College Hospital, Ibadan, Nigeria
4 Department of Chemical Pathology, Nile University of Nigeria, Abuja, Nigeria
|Date of Submission||08-Jun-2021|
|Date of Decision||10-Oct-2021|
|Date of Acceptance||12-Oct-2021|
|Date of Web Publication||27-Dec-2021|
Olatunde A Olayanju
Department of Chemical Pathology, Babcock University Teaching Hospital, Ilisan
Source of Support: None, Conflict of Interest: None
Background: Diabetes mellitus is a chronic disorder of glucose metabolism and it is associated with a compromised oral immunity. Salivary immunoglobulins offer a comprehensive protection for the oral cavity; however, there is insufficient data regarding their levels in type 2 diabetic patients. This study aimed to measure salivary Immunoglobulin G (IgG) and Immunoglobulin A (IgA) in diabetic patients in comparison to healthy nondiabetic controls. Methods: Diabetic patients from the outpatient clinic and nondiabetic healthy members of staff, were recruited for this study. Unstimulated saliva samples were collected from all participants and levels of immunoglobulins A and G were determined using enzyme-linked immunosorbent assay techniques; the values were compared between the two groups. Results: A total of 167 participants were recruited for this study, 95 (56.9%) of them were diabetic patients, while the remaining 72 (43.1%) were healthy nondiabetic controls. The median salivary IgA was 12.57 (Interquartile range [IQR] 11.05–13.67) g/ml in the diabetics and 11.94 (IQR 10.41–13.65) μg/ml in the control group; P = 0.31 while the median salivary IgG was 32.27 (IQR 25.26–38.33) μg/ml in the diabetics and 26.26 (22.48–31.29) μg/ml in the control group; P < 0.001. Conclusion: Salivary IgG was significantly elevated in the diabetic patients, in spite of a higher prevalence of oral infections, this calls for a more stringent attention to oral hygiene in diabetic patients.
Keywords: Diabetes, IgA, IgG, oral cavity, oral infection, saliva
|How to cite this article:|
Olayanju OA, Bamidele O, Eseile BJ, Udeh C, Odok GN, Awah NE, Mba IN, Abbiyesuku FM. Levels of salivary immunoglobulin a and immunoglobulin G in type 2 diabetic patients. Niger J Med 2021;30:665-9
|How to cite this URL:|
Olayanju OA, Bamidele O, Eseile BJ, Udeh C, Odok GN, Awah NE, Mba IN, Abbiyesuku FM. Levels of salivary immunoglobulin a and immunoglobulin G in type 2 diabetic patients. Niger J Med [serial online] 2021 [cited 2022 May 23];30:665-9. Available from: http://www.njmonline.org/text.asp?2021/30/6/665/333817
| Introduction|| |
Immunoglobulins are found in body fluids where they protect against infections. The blood, tears, saliva, mucosa secretions, synovial fluids, etc., have all provided useful information when evaluated for different types of immunoglobulins in different disease conditions. Salivary immunoglobulins for instance, have been studied in periodontitis, autoimmune diseases, chronic renal failure, and other systemic diseases., In the diabetics, salivary levels of several biochemical and immunological parameters have been evaluated, but some of the findings were equivocal.,, Immunoglobulin A (IgA), clearly the most commonly studied was elevated, reduced and indifferent, in several saliva studies, generating controversies regarding the relationship between diabetes and salivary immunoglobulins.,, Although it was not clear if there were confounders in the studies, what is generally apparent is the impaired protective functionality as evidenced by increased oral infections in the diabetics.,
Periodontal infections, tooth loss, and oral cancers all have increased prevalence in the diabetics;, burden and severity of these diseases have also been reported to be associated with the level of glucose control.,, A cardinal factor identified for this manifestation in chronic hyperglycemia is the dysfunctional immune system characterized by defective phagocytosis and chemotaxis by innate immune cells, resulting in unfettered proliferation of microbes in the oral cavity., The adaptive immune system also is not spared in diabetes; there are reports of B-cells dysfunction resulting in proliferation of sepsis and increased mortality in diabetic patients., Although most of the studies interrogating the relationship between infection and diabetes were done in blood samples reflecting an equally predominant systemic infections, salivary studies have also provided a good insight into how chronic hyperglycemia predisposes to increased susceptibility to oral infections.,
Serum Immunoglobulin G (IgG), IgA, and Immunoglobulin M (IgM) were reportedly reduced in patients with type 2 diabetes mellitus, and this was said to be implicated in the recurrent systemic infection in diabetic patients., In another study, while serum IgG and IgM were both reportedly reduced in Type 2 diabetic patients, serum IgA was elevated, unlike in the previous study. Other studies have reported various conflicting levels of these immunoglobulins, and they suggested different reasons for their findings, essentially highlighting generalized immune dysfunction., Given the positive correlation between the salivary and serum immunoglobulins as reported by yet other studies,, it is not surprising that the saliva which baths the oral cavity has shown similar trends with several studies reporting divergent opinions about the status of salivary immunoglobulins following chronic hyperglycemia in diabetic patients.,, This study is designed to determine the level of salivary IgA and IgG in Type 2 diabetic patients to establish how chronic hyperglycemia relates to oral cavity immune status.
| Methods|| |
This was a hospital-based cross-sectional study conducted on Type 2 diabetic patients attending the outpatient clinic; healthy nondiabetic members of staff served as the control group. Patients were systematically selected based on monthly clinic attendance data, and the study lasted about three months. Biodata and clinical information were collected from each participant using a structured questionnaire after obtaining informed consent from them.
Approval was duly obtained from the University of Ibadan/University College Hospital Ibadan Research Ethics Committee.
Sample collection and processing
Saliva samples were collected from participants in the morning after rinsing their mouths with clean water. They were asked to sit, bend their heads, open their mouth and passively drool saliva into a clean universal bottle. About 3 ml of saliva was collected, centrifuged at 3000 radian/min for 15 min, and the clear supernatant dispensed into a clean Eppendorf bottle for storage at-20 degrees centigrade until analysis was done; the study lasted about three months. Salivary IgG and IgA were analysed using enzyme-linked immunosorbent assay technique according to the manufacturer's instruction (Melsins Medicals, Changchun, China).
Qualitative variables were reported as number and percentages, quantitative variables as mean ± standard deviation (SD) if normally distributed and as median ± interquartile range (IQR) if not. Independent samples t-test was used to determine the statistical difference between the mean ± SD of normally distributed data, while Mann–Whitney U-test was used to determine statistical difference between data that were not normally distributed, between diabetic subjects and the healthy controls. Significance was set at P ≤ 0.05, an analysis was done using Statistical Package for Social Science (SPSS) version 26.0 (IBM Inc., Armonk, NY, USA).
| Results|| |
A total of 167 participants were recruited for this study and 82 (49.1%) of them were males. Ninety-five (56.9%) participants were type 2 diabetic patients, while the remaining 72 (43.1%) were healthy nondiabetic control group. There was no significant difference between the ages (P = 0.08) and weights (P = 0.43) of the two groups. However, the healthy controls were taller (P ≤ 0.001) and had a significantly lower body mass index [P = 0.002; [Table 1]]. Co-morbid conditions were compared between the two groups and there were more cases of hypertension (25 vs. 3), visual impairment (37 vs. 9), oral infections (9 vs. 2), and skin diseases (5 vs. 3) in the diabetic participants compared to the healthy controls. The salivary immunoglobulins were higher in the diabetic participants with salivary IgA measuring a median 12.57 (IQR 11.05–13.67) μg/ml compared to 11.94 (IQR 10.41–13.65) μg/ml in the healthy controls although the difference was not statistically significant (P = 0.31) [Figure 1]. The salivary IgG on the other hand was significantly elevated (P < 0.001) in the diabetic participants with a median of 32.27 (IQR 25.26––38.33) μg/ml [Figure 1] versus 26.26 (IQR 22.48–31.29) μg/ml in the healthy controls. Salivary IgA is significantly correlated positively with the Salivary IgG with a correlation coefficient of 0.372 and a P < 0.001. Salivary IgA and IgG were both positively correlated with the duration of diabetes treatment; correlation coefficients were 0.006 and 0.0068, respectively [Figure 2]. The correlation between the comorbidies and salivary IgA and IgG are presented in [Table 2].
|Table 1: Demographic characteristics of diabetic patients and nondiabetic control|
Click here to view
|Figure 1: Graphical presentation of salivary proteins comparison between patients and controls, showing the median values; error bars indicate the minimum and maximum values|
Click here to view
|Figure 2: Scatterplot showing the correlation between salivary immunoglobulin G and immunoglobulin A versus treatment duration in diabetic participants|
Click here to view
|Table 2: Correlations between the co-morbid conditions in the diabetic patients and salivary immunoglobulin A and immunoglobulin G|
Click here to view
| Discussion|| |
The increased prevalence of oral cavity infections in diabetic patients was suggestive of a characteristic oral immunosuppression;, this hypothesis was tested in this study by evaluating a major component of the oral immunity in the diabetics. Although the saliva is composed of a myriad of protective proteins, the immunoglobulins play a major role in safeguarding the integrity of the oral mucosa; thus, any alteration in secretion or functional impairment may be contributory to the high oral infection rate in the diabetics. In this study, we found elevated levels of salivary IgG in Type 2 diabetic patients compared to those in healthy nondiabetic control group. This finding was common in most of similar studies earlier reported, either in the blood or saliva,, and it was suggested that immune response to advanced glycosylation end product, a common sequela of chronic hyperglycemia, might be the trigger. Other studies, highlighting the protective function of the salivary immunoglobulins, arrogated the finding to increased immunoglobulins secretion against specific bacterial and fungal agents which occur more frequently in the diabetics.,,
The justification for elevated salivary immunoglobulins levels in the diabetics, as stated above, would suffice if they were effective and provide commensurate protection for the oral cavity. However, in spite of the increased immunoglobulins secretion, diabetics still present with more cases of oral infection compared to the nondiabetic population, this calls for a critical questioning of their functionality. A study in this regard indicated that chronicity of hyperglycemia, duration of treatment and genetic background of patients play significant roles. These may be explored in elucidating the contradiction that has characterised the findings in similar studies, given that the vast majority of the studies did not account for the duration of disease exposure, with or without treatment, during recruitment and data analysis., Time factor may suggest a gradual but progressive deterioration in functionality and quantity of salivary immunoglobulins, until a certain period when the drop becomes apparently measurable; a prospective study would be necessary to establish this consideration.
Given that the innate and the adaptive immune system are intricately intertwined, the crosstalk between the two systems provides an efficient protection within the oral cavity. However, the widespread dysfunction of the innate immune system which primarily offers the first line of defence against invading microbes, disrupts the synergy that exists between the two systems and the triggers necessary for effective immunoglobulin stimulation in the diabetics. The complement system, cytokine production and cellular activations which play important roles in immunoglobulins stimulation are also significantly dysfunctional. This may explain why salivary immunoglobulins are not produced in adequate amount, or fail to secure the oral cavity even when present in sufficient quantity in the diabetics., The initial drive executed by the innate immune system, is apparently lost or mostly ineffective, leading to a suboptimal adaptive immune response in the oral cavity.
This study showed a significant positive correlation between salivary IgA and IgG, indicating that protective proteins in the saliva move in the same direction in diabetic patients. This is not unexpected as both immunoglobulins are expected to respond to the increased susceptibility of diabetic patients to oral infection. A similar pattern has been described in patients with oral submucous fibrosis. This study also showed that salivary immunoglobulins are positively correlated with the duration of diabetic treatment suggesting that immunoglobulin secretion increases over time in diabetic patients possibly to circumvent increased susceptibility to infections.
There are a few limitations to this study. Only Type 2 diabetic patients were recruited for this study; inclusion of Type 1 diabetic patients may have been more inclusive and provided a broader outcome, but the role of immune dysregulation in the pathogenesis of Type 1 diabetes could contribute a confounder., Also, this is a cross sectional study in which no recourse was given to duration of exposure to diabetes, a longitudinal study where changes may be observed in the immunoglobulin level over a long period of time may add more flavour to the study.
| Conclusion|| |
Salivary immunoglobulin levels are higher in diabetic patients, even though prevalence of oral infection still surpasses that in the general population. This calls for a more stringent approach to management and oral hygiene in diabetic patients to ameliorate morbidity.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Oni P, Prehm P. Mutations in the Fc-region of IgG from synovial fluids of patients with rheumatoid arthritis. Cogent Med 2016;3:1221232.
Pallos D, Leão MV, Togeiro FC, Alegre L, Ricardo LH, Perozini C, et al.
Salivary markers in patients with chronic renal failure. Arch Oral Biol 2015;60:1784-8.
Darma A, Nugroho BS, Yoanna V, Sulistyani I, Athiyyah AF, Ranuh RG, et al.
Comparison of Helicobacter pylori
stool antigen, salivary IgG, serum IgG, and serum IgM as diagnostic markers of H. pylori
infection in children. Iran J Microbiol 2019;11:206-11.
Lima-Aragão MV, de Oliveira JD Jr., Maciel MC, Silva LA, do Nascimento FR, Guerra RN. Salivary profile in diabetic patients: Biochemical and immunological evaluation. BMC Res Notes 2016;9:103.
Sardari F, Tahmasbi A, Ghanbarzadegan A. Salivary IgA concentration in diabetic patients compared to healthy controls. Dent Hypotheses 2015;6:60. [Full text]
Martins RA, Costa FW, Silva SM, Silva PG, Carvalho FS, Fonteles CS, et al.
Salivary immunoglobulins (A, G, and M) in type 1 diabetes mellitus patients: A PROSPERO-registered systematic review and meta-analysis. Arch Oral Biol 2021;122:105025.
Abd-Elraheem SE, El Saeed AM, Mansour HH. Salivary changes in type 2 diabetic patients. Diabetes Metab Syndr 2017;11 Suppl 2:S637-41.
Ahmadiafshar A, Mohsenifard MR, Mazloomzadeh S. Evaluation of serum & salivary IgA in patients with type 1 diabetes. PLoS One 2015;10:e0122757.
Hegde SS, Sattur AP, Bargale AB, Rao GS, Shetty RS, Kulkarni RD, et al.
Estimation and correlation of serum and salivary glucose and immunoglobulin A levels and salivary candidal carriage in diabetic and non-diabetic patients. J Dent Res Dent Clin Dent Prospects 2020;14:206-13.
Graves DT, Ding Z, Yang Y. The impact of diabetes on periodontal diseases. Periodontol 2000;82:214-24.
Mauri-Obradors E, Estrugo-Devesa A, Jané-Salas E, Viñas M, López-López J. Oral manifestations of diabetes mellitus. A systematic review. Med Oral Patol Oral Cir Bucal 2017;22:e586.
D'Aiuto F, Gable D, Syed Z, Allen Y, Wanyonyi KL, White S, et al.
Evidence summary: The relationship between oral diseases and diabetes. Br Dent J 2017;222:944-8.
Nazir MA, AlGhamdi L, AlKadi M, AlBeajan N, AlRashoudi L, AlHussan M. The burden of diabetes, its oral complications and their prevention and management. Open Access Maced J Med Sci 2018;6:1545-53.
Demmer RT, Breskin A, Rosenbaum M, Zuk A, LeDuc C, Leibel R, et al.
The subgingival microbiome, systemic inflammation and insulin resistance: The oral infections, glucose intolerance and insulin resistance study. J Clin Periodontol 2017;44:255-65.
Xiao E, Mattos M, Vieira GH, Chen S, Corrêa JD, Wu Y, et al.
Diabetes enhances IL-17 expression and alters the oral microbiome to increase its pathogenicity. Cell Host Microbe 2017;22:120-8.e4.
Tsai C, Hayes C, Taylor GW. Glycemic control of Type 2 diabetes and severe periodontal disease in the US adult population. Community Dent Oral Epidemiol 2002;30:182-92.
Casqueiro J, Casqueiro J, Alves C. Infections in patients with diabetes mellitus: A review of pathogenesis. Indian J Endocrinol Metab 2012;16 Suppl 1:S27-36.
Peleg AY, Weerarathna T, McCarthy JS, Davis TM. Common infections in diabetes: Pathogenesis, management and relationship to glycaemic control. Diabetes Metab Res Rev 2007;23:3-13.
Zhou T, Hu Z, Yang S, Sun L, Yu Z, Wang G. Role of adaptive and innate immunity in Type 2 diabetes mellitus. J Diabetes Res 2018;2018:7457269.
Frydrych LM, Bian G, O'Lone DE, Ward PA, Delano MJ. Obesity and Type 2 diabetes mellitus drive immune dysfunction, infection development, and sepsis mortality. J Leukoc Biol 2018;104:525-34.
RF, A J. Assessment of immune response in patients with type 2 diabetes mellitus. Ann Trop Med Public Health 2020;23:S432.
Oikawa J, Ukawa S, Ohira H, Kawamura T, Wakai K, Ando M, et al.
Diabetes mellitus is associated with low secretion rates of immunoglobulin A in saliva. J Epidemiol 2015;25:470-4.
Guo X, Meng G, Liu F, Zhang Q, Liu L, Wu H, et al.
Serum levels of immunoglobulins in an adult population and their relationship with type 2 diabetes. Diabetes Res Clin Pract 2016;115:76-82.
Akinlade KS, Arinola OG, Salimonu LS, Oyeyinka GO. Circulating immune complexes, immunoglobulin classes (IgG, IgA and IgM) and complement components (C3c, C4 and Factor B) in diabetic Nigerians. West Afr J Med 2004;23:253-5.
Awartani F. Serum immunoglobulin levels in type 2 diabetes patients with chronic periodontitis. J Contemp Dent Pract 2010;11:001-8.
Patidar KA, Parwani RN, Wanjari SP. Correlation of salivary and serum IgG, IgA levels with total protein in oral submucous fibrosis. J Oral Sci 2011;53:97-102.
Pineda-Martínez S, Hernández-Islas JL, Escobedo-Torres MP, Paredes-Alonzo IE, López-Candiani C, Correa D, et al.
Immunoglobulin concentrations in plasma and saliva during the neonatal period. Pediatr Neonatol 2016;57:213-8.
Carey IM, Critchley JA, DeWilde S, Harris T, Hosking FJ, Cook DG. Risk of infection in Type 1 and Type 2 diabetes compared with the general population: A matched cohort study. Diabetes Care 2018;41:513-21.
Akash MS, Rehman K, Fiayyaz F, Sabir S, Khurshid M. Diabetes-associated infections: Development of antimicrobial resistance and possible treatment strategies. Arch Microbiol 2020;202:953-65.
Wang K, Zhou X, Li W, Zhang L. Human salivary proteins and their peptidomimetics: Values of function, early diagnosis, and therapeutic potential in combating dental caries. Arch Oral Biol 2019;99:31-42.
Hoddinott S, Dornan J, Bear JC, Farid NR. Immunoglobulin levels, immunodeficiency and HLA in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1982;23:326-9.
Greco D, Maggio F. Selective immunoglobulin a deficiency in type 1 diabetes mellitus: A prevalence study in Western Sicily (Italy). Diabetes Metab J 2015;39:132-6.
Clark R, Kupper T. Old meets new: The interaction between innate and adaptive immunity. J Invest Dermatol 2005;125:629-37.
Geerlings SE, Hoepelman AI. Immune dysfunction in patients with diabetes mellitus (DM). FEMS Immunol Med Microbiol 1999;26:259-65.
Reschner A, Hubert P, Delvenne P, Boniver J, Jacobs N. Innate lymphocyte and dendritic cell cross-talk: A key factor in the regulation of the immune response. Clin Exp Immunol 2008;152:219-26.
Zingoni A, Sornasse T, Cocks BG, Tanaka Y, Santoni A, Lanier LL. Cross-talk between activated human NK cells and CD4+ T cells via OX40-OX40 ligand interactions. J Immunol 2004;173:3716-24.
Zóka A, MÅ±zes G, Somogyi A, Varga T, Szémán B, Al-Aissa Z, et al.
Altered immune regulation in type 1 diabetes. Clin Dev Immunol 2013;2013:254874.
Wållberg M, Cooke A. Immune mechanisms in type 1 diabetes. Trends Immunol 2013;34:583-91.
[Figure 1], [Figure 2]
[Table 1], [Table 2]